Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.

Saved in:
Bibliographic Details
Title: Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.
Authors: Mercuri FA; ENA Respiratory, Melbourne, VIC, Australia.; These authors contributed equally., White S; ENA Respiratory, Melbourne, VIC, Australia.; These authors contributed equally., McQuilten HA; ENA Respiratory, Melbourne, VIC, Australia., Lemech C; Scientia Clinical Research Ltd, Randwick, NSW, Australia.; Prince of Wales Clinical School, UNSW, Sydney, NSW, Australia., Mynhardt S; Resolutum Global Pty Ltd, VIC, Australia., Hari R; Scientia Clinical Research Ltd, Randwick, NSW, Australia., Zhang P; Griffith Biostatistics Unit, Griffith Health, Griffith University Gold Coast Campus, QLD, Australia., Kruger N; ENA Respiratory, Melbourne, VIC, Australia., McLachlan G; ENA Respiratory, Melbourne, VIC, Australia., Miller BE; ENA Respiratory, Melbourne, VIC, Australia., West NP; School of Pharmacy and Medical Science and the Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, QLD, Australia., Tal-Singer R; ENA Respiratory, Melbourne, VIC, Australia., Demaison C; ENA Respiratory, Melbourne, VIC, Australia.
Source: ERJ open research [ERJ Open Res] 2024 Dec 09; Vol. 10 (6). Date of Electronic Publication: 2024 Dec 09 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2312-0541
DOI:10.1183/23120541.00199-2024